Allergic Conjunctivitis Market By Drug Class, By Disease Type (Seasonal Allergic Conjunctivitis, Perennial Allergic Conjunctivitis ), By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

PUBLISHED: July 1, 2022

PAGES: 303 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The global allergic conjunctivitis market was valued at $1,937.99 million in 2021, and is estimated to reach $2,954.2 million by 2031, growing at a CAGR of 4.28%% from 2022 to 2031.

An allergic reaction to things such as pollen, mold, or spores can result in an eye inflammation known as allergic conjunctivitis. The conjunctiva is a membrane that covers the interior of the eyelids and the surface of the eyeball. Allergens can irritate the conjunctiva, especially during the hay fever season. Conjunctivitis due to an allergy is extremely prevalent. It is a response by individual's body to chemicals that it seems to be potentially dangerous.

Conjunctivitis caused by allergens is one of the most commonly occurring allergies. According to the Asthma and Allergy Foundation of America, allergies run in families and impact 30% of adults and 40% of children. Common signs of allergic conjunctivitis include red, watery, burning, and itchy eyes. It's also possible to have puffy eyes when one first wake up in the morning.

The major factors that drive the growth of the allergic conjunctivitis market are increase in patient population suffering from ocular allergies. According to National Centre of medicine allergic conjunctivitis or conjunctival symptoms are present in 30-71% of patients with allergic rhinitis as many people are suffering from allergic conjunctivitis demand for drugs increases. In addition, many key market players are focusing on R&D activities to develop new drugs for the treatment of ocular allergies is a key trend of the market, which is expected to fuel the growth in the forecast period.

Furthermore, poor hygienic practices such as touching eyes with unclean hands, using contaminated makeup & lotions causes ocular allergy, which is anticipated to drive the market growth in the near future. Rise in prevalence of sexually transmitted diseases tends to drive the market growth. The most prevalent STIs are chlamydia and gonorrhoea, and both can result in conjunctivitis. Either directly through sexual fluids like semen or when infected individuals rub their eyes after contacting infected genital areas, which are the two ways the illness enters the eye. Thus, such high number of cases are expected to boost the allergic conjunctivitis procedures.

However, unfavorable reimbursements scenarios and lack of awareness of ocular allergies are expected to hinder the growth of the market. Conversely, rapid rise in urbanization leads to more exposure to chemicals and pollutants in both developed and developing countries, which is expected to provide a great opportunity for the investors to invest in the market.

The global allergic conjunctivitis market is segmented on the basis of drug class, disease type, distribution channel, and region. On the basis of drug class, the market is categorized into antihistamines & mast cell, corticosteroids, and others. By disease type, it is divided into seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC). The seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) each are further sub segmented by age group into adult and pediatric. By distribution channel, it is segmented into hospital pharmacies, drug store & retail pharmacies and online providers. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).

The major players profiled in the report are AbbVie Inc., Ajanta Pharma Limited, Akron Operating Company LLC, Alembic Pharmaceuticals Ltd, Bausch Health Companies Inc , Cipla, Inc., Grevis Pharmaceutical Private Limited , Indoco Remedies Ltd., Jabs Biotech Pvt. Ltd., JAWA Pharmaceuticals Pvt. Ltd, Johnson & Johnson Services Inc., Novartis AG, Ocular Therapeutics, Inc., Santen Pharmaceuticals Co. Ltd., Spectra Vision Care Pvt. Ltd, Sun Pharmaceuticals Industries Ltd andTeva Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the allergic conjunctivitis market analysis from 2021 to 2031 to identify the prevailing allergic conjunctivitis market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the allergic conjunctivitis market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global allergic conjunctivitis market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

Antihistamines Mast Cell Stabilizers
Corticosteroids
Others

By Disease Type

Seasonal Allergic Conjunctivitis (SAC)
Perennial Allergic Conjunctivitis (PAC)

By Distribution Channel

Hospital Pharmacies
Drug stores Retail Pharmacies
Online providers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- AbbVie Inc.
- Ajanta Pharma Limited
- Akron Operating Company LLC
- Alembic Pharmaceuticals Ltd.
- Bausch Health Companies Inc.
- Cipla Ltd
- Grevis Pharmaceutical Private Limited
- Indoco Remedies Ltd.
- Jabs Biotech Pvt. Ltd.
- JAWA Pharmaceuticals Pvt. Ltd.
- Johnson and Johnson
- Novartis AG
- Ocular Therapeutics, Inc.
- Santen Pharmaceuticals Co. Ltd.
- Spectra Vision Care Pvt. Ltd.
- Sun Pharmaceuticals Industries Ltd
- Teva Pharmaceutical Industries Ltd.

Product Code: A17093

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Antihistamines & Mast Cell Stabilizers
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Corticosteroids
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
4.4 Others
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country

CHAPTER 5: ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Seasonal Allergic Conjunctivitis (SAC)
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Perennial Allergic Conjunctivitis (PAC)
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country

CHAPTER 6: ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Hospital Pharmacies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Drug stores & Retail Pharmacies
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
6.4 Online providers
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country

CHAPTER 7: ALLERGIC CONJUNCTIVITIS MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Drug Class
- 7.2.3 North America Market size and forecast, by Disease Type
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Market size and forecast, by Drug Class
  - 7.2.5.1.2 Market size and forecast, by Disease Type
  - 7.2.5.1.3 Market size and forecast, by Distribution Channel
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Market size and forecast, by Drug Class
  - 7.2.5.2.2 Market size and forecast, by Disease Type
  - 7.2.5.2.3 Market size and forecast, by Distribution Channel
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Market size and forecast, by Drug Class
  - 7.2.5.3.2 Market size and forecast, by Disease Type
  - 7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Drug Class
- 7.3.3 Europe Market size and forecast, by Disease Type
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 Germany
  - 7.3.5.1.1 Market size and forecast, by Drug Class
  - 7.3.5.1.2 Market size and forecast, by Disease Type
  - 7.3.5.1.3 Market size and forecast, by Distribution Channel
  - 7.3.5.2 France
  - 7.3.5.2.1 Market size and forecast, by Drug Class
  - 7.3.5.2.2 Market size and forecast, by Disease Type
  - 7.3.5.2.3 Market size and forecast, by Distribution Channel
  - 7.3.5.3 UK
  - 7.3.5.3.1 Market size and forecast, by Drug Class
  - 7.3.5.3.2 Market size and forecast, by Disease Type
  - 7.3.5.3.3 Market size and forecast, by Distribution Channel
  - 7.3.5.4 Italy
  - 7.3.5.4.1 Market size and forecast, by Drug Class
  - 7.3.5.4.2 Market size and forecast, by Disease Type
  - 7.3.5.4.3 Market size and forecast, by Distribution Channel
  - 7.3.5.5 Spain
  - 7.3.5.5.1 Market size and forecast, by Drug Class
  - 7.3.5.5.2 Market size and forecast, by Disease Type
  - 7.3.5.5.3 Market size and forecast, by Distribution Channel
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Market size and forecast, by Drug Class
  - 7.3.5.6.2 Market size and forecast, by Disease Type
  - 7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Drug Class
- 7.4.3 Asia-Pacific Market size and forecast, by Disease Type
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 Japan
  - 7.4.5.1.1 Market size and forecast, by Drug Class
  - 7.4.5.1.2 Market size and forecast, by Disease Type
  - 7.4.5.1.3 Market size and forecast, by Distribution Channel
  - 7.4.5.2 China
  - 7.4.5.2.1 Market size and forecast, by Drug Class
  - 7.4.5.2.2 Market size and forecast, by Disease Type
  - 7.4.5.2.3 Market size and forecast, by Distribution Channel
  - 7.4.5.3 Australia
  - 7.4.5.3.1 Market size and forecast, by Drug Class
  - 7.4.5.3.2 Market size and forecast, by Disease Type
  - 7.4.5.3.3 Market size and forecast, by Distribution Channel
  - 7.4.5.4 India
  - 7.4.5.4.1 Market size and forecast, by Drug Class
  - 7.4.5.4.2 Market size and forecast, by Disease Type
  - 7.4.5.4.3 Market size and forecast, by Distribution Channel
  - 7.4.5.5 South Korea
  - 7.4.5.5.1 Market size and forecast, by Drug Class
  - 7.4.5.5.2 Market size and forecast, by Disease Type
  - 7.4.5.5.3 Market size and forecast, by Distribution Channel
  - 7.4.5.6 Rest of Asia-Pacific
  - 7.4.5.6.1 Market size and forecast, by Drug Class
  - 7.4.5.6.2 Market size and forecast, by Disease Type
  - 7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Drug Class
- 7.5.3 LAMEA Market size and forecast, by Disease Type
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Market size and forecast, by Drug Class
  - 7.5.5.1.2 Market size and forecast, by Disease Type
  - 7.5.5.1.3 Market size and forecast, by Distribution Channel
  - 7.5.5.2 Saudi Arabia
  - 7.5.5.2.1 Market size and forecast, by Drug Class
  - 7.5.5.2.2 Market size and forecast, by Disease Type
  - 7.5.5.2.3 Market size and forecast, by Distribution Channel
  - 7.5.5.3 South Africa
  - 7.5.5.3.1 Market size and forecast, by Drug Class
  - 7.5.5.3.2 Market size and forecast, by Disease Type
  - 7.5.5.3.3 Market size and forecast, by Distribution Channel
  - 7.5.5.4 Rest of LAMEA
  - 7.5.5.4.1 Market size and forecast, by Drug Class
  - 7.5.5.4.2 Market size and forecast, by Disease Type
  - 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 AbbVie Inc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 Ajanta Pharma Limited
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 Akron Operating Company LLC
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 Alembic Pharmaceuticals Ltd.
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 Bausch Health Companies Inc.
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 Cipla Ltd
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Grevis Pharmaceutical Private Limited
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 Indoco Remedies Ltd.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 Jabs Biotech Pvt. Ltd.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 JAWA Pharmaceuticals Pvt. Ltd.
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
9.11 Johnson and Johnson
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
9.12 Novartis AG
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments
9.13 Ocular Therapeutics, Inc.
- 9.13.1 Company overview
- 9.13.2 Company snapshot
- 9.13.3 Operating business segments
- 9.13.4 Product portfolio
- 9.13.5 Business performance
- 9.13.6 Key strategic moves and developments
9.14 Santen Pharmaceuticals Co. Ltd.
- 9.14.1 Company overview
- 9.14.2 Company snapshot
- 9.14.3 Operating business segments
- 9.14.4 Product portfolio
- 9.14.5 Business performance
- 9.14.6 Key strategic moves and developments
9.15 Spectra Vision Care Pvt. Ltd.
- 9.15.1 Company overview
- 9.15.2 Company snapshot
- 9.15.3 Operating business segments
- 9.15.4 Product portfolio
- 9.15.5 Business performance
- 9.15.6 Key strategic moves and developments
9.16 Sun Pharmaceuticals Industries Ltd
- 9.16.1 Company overview
- 9.16.2 Company snapshot
- 9.16.3 Operating business segments
- 9.16.4 Product portfolio
- 9.16.5 Business performance
- 9.16.6 Key strategic moves and developments
9.17 Teva Pharmaceutical Industries Ltd.
- 9.17.1 Company overview
- 9.17.2 Company snapshot
- 9.17.3 Operating business segments
- 9.17.4 Product portfolio
- 9.17.5 Business performance
- 9.17.6 Key strategic moves and developments

Product Code: A17093

LIST OF TABLES

TABLE 1. GLOBAL ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 2. ALLERGIC CONJUNCTIVITIS MARKET SIZE, FOR ANTIHISTAMINES & MAST CELL STABILIZERS, BY REGION, 2021-2031 ($MILLION)
TABLE 3. ALLERGIC CONJUNCTIVITIS MARKET FOR ANTIHISTAMINES & MAST CELL STABILIZERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. ALLERGIC CONJUNCTIVITIS MARKET SIZE, FOR CORTICOSTEROIDS, BY REGION, 2021-2031 ($MILLION)
TABLE 5. ALLERGIC CONJUNCTIVITIS MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. ALLERGIC CONJUNCTIVITIS MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 7. ALLERGIC CONJUNCTIVITIS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. GLOBAL ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 9. ALLERGIC CONJUNCTIVITIS MARKET SIZE, FOR SEASONAL ALLERGIC CONJUNCTIVITIS (SAC), BY REGION, 2021-2031 ($MILLION)
TABLE 10. ALLERGIC CONJUNCTIVITIS MARKET FOR SEASONAL ALLERGIC CONJUNCTIVITIS (SAC), BY COUNTRY, 2021-2031 ($MILLION)
TABLE 11. ALLERGIC CONJUNCTIVITIS MARKET SIZE, FOR PERENNIAL ALLERGIC CONJUNCTIVITIS (PAC), BY REGION, 2021-2031 ($MILLION)
TABLE 12. ALLERGIC CONJUNCTIVITIS MARKET FOR PERENNIAL ALLERGIC CONJUNCTIVITIS (PAC), BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. GLOBAL ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 14. ALLERGIC CONJUNCTIVITIS MARKET SIZE, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 15. ALLERGIC CONJUNCTIVITIS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 16. ALLERGIC CONJUNCTIVITIS MARKET SIZE, FOR DRUG STORES & RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 17. ALLERGIC CONJUNCTIVITIS MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 18. ALLERGIC CONJUNCTIVITIS MARKET SIZE, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 19. ALLERGIC CONJUNCTIVITIS MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 20. ALLERGIC CONJUNCTIVITIS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 21. NORTH AMERICA ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 22. NORTH AMERICA ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 23. NORTH AMERICA ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 24. NORTH AMERICA ALLERGIC CONJUNCTIVITIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 25. U.S. ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 26. U.S. ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 27. U.S. ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 28. CANADA ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 29. CANADA ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 30. CANADA ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 31. MEXICO ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 32. MEXICO ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 33. MEXICO ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 34. EUROPE ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 35. EUROPE ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 36. EUROPE ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 37. EUROPE ALLERGIC CONJUNCTIVITIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 38. GERMANY ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 39. GERMANY ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 40. GERMANY ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 41. FRANCE ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 42. FRANCE ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 43. FRANCE ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 44. UK ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 45. UK ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 46. UK ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 47. ITALY ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 48. ITALY ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 49. ITALY ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 50. SPAIN ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 51. SPAIN ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 52. SPAIN ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 53. REST OF EUROPE ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 54. REST OF EUROPE ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 55. REST OF EUROPE ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 56. ASIA-PACIFIC ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 57. ASIA-PACIFIC ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 58. ASIA-PACIFIC ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 59. ASIA-PACIFIC ALLERGIC CONJUNCTIVITIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 60. JAPAN ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 61. JAPAN ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 62. JAPAN ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 63. CHINA ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 64. CHINA ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 65. CHINA ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 66. AUSTRALIA ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 67. AUSTRALIA ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 68. AUSTRALIA ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 69. INDIA ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 70. INDIA ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 71. INDIA ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 72. SOUTH KOREA ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 73. SOUTH KOREA ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 74. SOUTH KOREA ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 75. REST OF ASIA-PACIFIC ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 76. REST OF ASIA-PACIFIC ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 77. REST OF ASIA-PACIFIC ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 78. LAMEA ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 79. LAMEA ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 80. LAMEA ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 81. LAMEA ALLERGIC CONJUNCTIVITIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 82. BRAZIL ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 83. BRAZIL ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 84. BRAZIL ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 85. SAUDI ARABIA ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 86. SAUDI ARABIA ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 87. SAUDI ARABIA ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 88. SOUTH AFRICA ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 89. SOUTH AFRICA ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 90. SOUTH AFRICA ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 91. REST OF LAMEA ALLERGIC CONJUNCTIVITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 92. REST OF LAMEA ALLERGIC CONJUNCTIVITIS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 93. REST OF LAMEA ALLERGIC CONJUNCTIVITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 94.ABBVIE INC.: COMPANY SNAPSHOT
TABLE 95.ABBVIE INC.: OPERATING SEGMENTS
TABLE 96.ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 97.ABBVIE INC.: NET SALES,
TABLE 98.ABBVIE INC.: KEY STRATERGIES
TABLE 99.AJANTA PHARMA LIMITED: COMPANY SNAPSHOT
TABLE 100.AJANTA PHARMA LIMITED: OPERATING SEGMENTS
TABLE 101.AJANTA PHARMA LIMITED: PRODUCT PORTFOLIO
TABLE 102.AJANTA PHARMA LIMITED: NET SALES,
TABLE 103.AJANTA PHARMA LIMITED: KEY STRATERGIES
TABLE 104.AKRON OPERATING COMPANY LLC: COMPANY SNAPSHOT
TABLE 105.AKRON OPERATING COMPANY LLC: OPERATING SEGMENTS
TABLE 106.AKRON OPERATING COMPANY LLC: PRODUCT PORTFOLIO
TABLE 107.AKRON OPERATING COMPANY LLC: NET SALES,
TABLE 108.AKRON OPERATING COMPANY LLC: KEY STRATERGIES
TABLE 109.ALEMBIC PHARMACEUTICALS LTD.: COMPANY SNAPSHOT
TABLE 110.ALEMBIC PHARMACEUTICALS LTD.: OPERATING SEGMENTS
TABLE 111.ALEMBIC PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
TABLE 112.ALEMBIC PHARMACEUTICALS LTD.: NET SALES,
TABLE 113.ALEMBIC PHARMACEUTICALS LTD.: KEY STRATERGIES
TABLE 114.BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
TABLE 115.BAUSCH HEALTH COMPANIES INC.: OPERATING SEGMENTS
TABLE 116.BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
TABLE 117.BAUSCH HEALTH COMPANIES INC.: NET SALES,
TABLE 118.BAUSCH HEALTH COMPANIES INC.: KEY STRATERGIES
TABLE 119.CIPLA LTD: COMPANY SNAPSHOT
TABLE 120.CIPLA LTD: OPERATING SEGMENTS
TABLE 121.CIPLA LTD: PRODUCT PORTFOLIO
TABLE 122.CIPLA LTD: NET SALES,
TABLE 123.CIPLA LTD: KEY STRATERGIES
TABLE 124.GREVIS PHARMACEUTICAL PRIVATE LIMITED: COMPANY SNAPSHOT
TABLE 125.GREVIS PHARMACEUTICAL PRIVATE LIMITED: OPERATING SEGMENTS
TABLE 126.GREVIS PHARMACEUTICAL PRIVATE LIMITED: PRODUCT PORTFOLIO
TABLE 127.GREVIS PHARMACEUTICAL PRIVATE LIMITED: NET SALES,
TABLE 128.GREVIS PHARMACEUTICAL PRIVATE LIMITED: KEY STRATERGIES
TABLE 129.INDOCO REMEDIES LTD.: COMPANY SNAPSHOT
TABLE 130.INDOCO REMEDIES LTD.: OPERATING SEGMENTS
TABLE 131.INDOCO REMEDIES LTD.: PRODUCT PORTFOLIO
TABLE 132.INDOCO REMEDIES LTD.: NET SALES,
TABLE 133.INDOCO REMEDIES LTD.: KEY STRATERGIES
TABLE 134.JABS BIOTECH PVT. LTD.: COMPANY SNAPSHOT
TABLE 135.JABS BIOTECH PVT. LTD.: OPERATING SEGMENTS
TABLE 136.JABS BIOTECH PVT. LTD.: PRODUCT PORTFOLIO
TABLE 137.JABS BIOTECH PVT. LTD.: NET SALES,
TABLE 138.JABS BIOTECH PVT. LTD.: KEY STRATERGIES
TABLE 139.JAWA PHARMACEUTICALS PVT. LTD.: COMPANY SNAPSHOT
TABLE 140.JAWA PHARMACEUTICALS PVT. LTD.: OPERATING SEGMENTS
TABLE 141.JAWA PHARMACEUTICALS PVT. LTD.: PRODUCT PORTFOLIO
TABLE 142.JAWA PHARMACEUTICALS PVT. LTD.: NET SALES,
TABLE 143.JAWA PHARMACEUTICALS PVT. LTD.: KEY STRATERGIES
TABLE 144.JOHNSON AND JOHNSON: COMPANY SNAPSHOT
TABLE 145.JOHNSON AND JOHNSON: OPERATING SEGMENTS
TABLE 146.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 147.JOHNSON AND JOHNSON: NET SALES,
TABLE 148.JOHNSON AND JOHNSON: KEY STRATERGIES
TABLE 149.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 150.NOVARTIS AG: OPERATING SEGMENTS
TABLE 151.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 152.NOVARTIS AG: NET SALES,
TABLE 153.NOVARTIS AG: KEY STRATERGIES
TABLE 154.OCULAR THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 155.OCULAR THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE 156.OCULAR THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 157.OCULAR THERAPEUTICS, INC.: NET SALES,
TABLE 158.OCULAR THERAPEUTICS, INC.: KEY STRATERGIES
TABLE 159.SANTEN PHARMACEUTICALS CO. LTD.: COMPANY SNAPSHOT
TABLE 160.SANTEN PHARMACEUTICALS CO. LTD.: OPERATING SEGMENTS
TABLE 161.SANTEN PHARMACEUTICALS CO. LTD.: PRODUCT PORTFOLIO
TABLE 162.SANTEN PHARMACEUTICALS CO. LTD.: NET SALES,
TABLE 163.SANTEN PHARMACEUTICALS CO. LTD.: KEY STRATERGIES
TABLE 164.SPECTRA VISION CARE PVT. LTD.: COMPANY SNAPSHOT
TABLE 165.SPECTRA VISION CARE PVT. LTD.: OPERATING SEGMENTS
TABLE 166.SPECTRA VISION CARE PVT. LTD.: PRODUCT PORTFOLIO
TABLE 167.SPECTRA VISION CARE PVT. LTD.: NET SALES,
TABLE 168.SPECTRA VISION CARE PVT. LTD.: KEY STRATERGIES
TABLE 169.SUN PHARMACEUTICALS INDUSTRIES LTD: COMPANY SNAPSHOT
TABLE 170.SUN PHARMACEUTICALS INDUSTRIES LTD: OPERATING SEGMENTS
TABLE 171.SUN PHARMACEUTICALS INDUSTRIES LTD: PRODUCT PORTFOLIO
TABLE 172.SUN PHARMACEUTICALS INDUSTRIES LTD: NET SALES,
TABLE 173.SUN PHARMACEUTICALS INDUSTRIES LTD: KEY STRATERGIES
TABLE 174.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 175.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 176.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 177.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
TABLE 178.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES

LIST OF FIGURES

FIGURE 1.ALLERGIC CONJUNCTIVITIS MARKET SEGMENTATION
FIGURE 2.ALLERGIC CONJUNCTIVITIS MARKET,2021-2031
FIGURE 3.ALLERGIC CONJUNCTIVITIS MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.ALLERGIC CONJUNCTIVITIS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.ALLERGIC CONJUNCTIVITIS MARKET,BY DRUG CLASS,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANTIHISTAMINES & MAST CELL STABILIZERS ALLERGIC CONJUNCTIVITIS MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF CORTICOSTEROIDS ALLERGIC CONJUNCTIVITIS MARKET,2021-2031(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF OTHERS ALLERGIC CONJUNCTIVITIS MARKET,2021-2031(%)
FIGURE 16.ALLERGIC CONJUNCTIVITIS MARKET,BY DISEASE TYPE,2021(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF SEASONAL ALLERGIC CONJUNCTIVITIS (SAC) ALLERGIC CONJUNCTIVITIS MARKET,2021-2031(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF PERENNIAL ALLERGIC CONJUNCTIVITIS (PAC) ALLERGIC CONJUNCTIVITIS MARKET,2021-2031(%)
FIGURE 19.ALLERGIC CONJUNCTIVITIS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES ALLERGIC CONJUNCTIVITIS MARKET,2021-2031(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF DRUG STORES & RETAIL PHARMACIES ALLERGIC CONJUNCTIVITIS MARKET,2021-2031(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS ALLERGIC CONJUNCTIVITIS MARKET,2021-2031(%)
FIGURE 23.ALLERGIC CONJUNCTIVITIS MARKET BY REGION,2021
FIGURE 24.U.S. ALLERGIC CONJUNCTIVITIS MARKET,2021-2031($MILLION)
FIGURE 25.CANADA ALLERGIC CONJUNCTIVITIS MARKET,2021-2031($MILLION)
FIGURE 26.MEXICO ALLERGIC CONJUNCTIVITIS MARKET,2021-2031($MILLION)
FIGURE 27.GERMANY ALLERGIC CONJUNCTIVITIS MARKET,2021-2031($MILLION)
FIGURE 28.FRANCE ALLERGIC CONJUNCTIVITIS MARKET,2021-2031($MILLION)
FIGURE 29.UK ALLERGIC CONJUNCTIVITIS MARKET,2021-2031($MILLION)
FIGURE 30.ITALY ALLERGIC CONJUNCTIVITIS MARKET,2021-2031($MILLION)
FIGURE 31.SPAIN ALLERGIC CONJUNCTIVITIS MARKET,2021-2031($MILLION)
FIGURE 32.REST OF EUROPE ALLERGIC CONJUNCTIVITIS MARKET,2021-2031($MILLION)
FIGURE 33.JAPAN ALLERGIC CONJUNCTIVITIS MARKET,2021-2031($MILLION)
FIGURE 34.CHINA ALLERGIC CONJUNCTIVITIS MARKET,2021-2031($MILLION)
FIGURE 35.AUSTRALIA ALLERGIC CONJUNCTIVITIS MARKET,2021-2031($MILLION)
FIGURE 36.INDIA ALLERGIC CONJUNCTIVITIS MARKET,2021-2031($MILLION)
FIGURE 37.SOUTH KOREA ALLERGIC CONJUNCTIVITIS MARKET,2021-2031($MILLION)
FIGURE 38.REST OF ASIA-PACIFIC ALLERGIC CONJUNCTIVITIS MARKET,2021-2031($MILLION)
FIGURE 39.BRAZIL ALLERGIC CONJUNCTIVITIS MARKET,2021-2031($MILLION)
FIGURE 40.SAUDI ARABIA ALLERGIC CONJUNCTIVITIS MARKET,2021-2031($MILLION)
FIGURE 41.SOUTH AFRICA ALLERGIC CONJUNCTIVITIS MARKET,2021-2031($MILLION)
FIGURE 42.REST OF LAMEA ALLERGIC CONJUNCTIVITIS MARKET,2021-2031($MILLION)
FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 46.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 47.COMPETITIVE DASHBOARD
FIGURE 48.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 49.ABBVIE INC..: NET SALES ,($MILLION)
FIGURE 50.AJANTA PHARMA LIMITED.: NET SALES ,($MILLION)
FIGURE 51.AKRON OPERATING COMPANY LLC.: NET SALES ,($MILLION)
FIGURE 52.ALEMBIC PHARMACEUTICALS LTD..: NET SALES ,($MILLION)
FIGURE 53.BAUSCH HEALTH COMPANIES INC..: NET SALES ,($MILLION)
FIGURE 54.CIPLA LTD.: NET SALES ,($MILLION)
FIGURE 55.GREVIS PHARMACEUTICAL PRIVATE LIMITED.: NET SALES ,($MILLION)
FIGURE 56.INDOCO REMEDIES LTD..: NET SALES ,($MILLION)
FIGURE 57.JABS BIOTECH PVT. LTD..: NET SALES ,($MILLION)
FIGURE 58.JAWA PHARMACEUTICALS PVT. LTD..: NET SALES ,($MILLION)
FIGURE 59.JOHNSON AND JOHNSON.: NET SALES ,($MILLION)
FIGURE 60.NOVARTIS AG.: NET SALES ,($MILLION)
FIGURE 61.OCULAR THERAPEUTICS, INC..: NET SALES ,($MILLION)
FIGURE 62.SANTEN PHARMACEUTICALS CO. LTD..: NET SALES ,($MILLION)
FIGURE 63.SPECTRA VISION CARE PVT. LTD..: NET SALES ,($MILLION)
FIGURE 64.SUN PHARMACEUTICALS INDUSTRIES LTD.: NET SALES ,($MILLION)
FIGURE 65.TEVA PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ,($MILLION)